ADMA · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
ADMA Biologics, Inc. (the “Company”) will be unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) within the prescribed time period without unreasonable effort or expense. As disclosed on its Current Report on Form 8-K filed on October 9, 2024, the Company’s previous independent registered public accounting firm resigned effective as of the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. The Company engaged KPMG LLP as its new independent registered public accounting firm effective as of the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, which was filed on November 7, 2024. The Company requires additional time to test and document the Company’s controls associated with its use of and reliance upon certain third-party service providers and to complete its assessment of the effectiveness of internal control over financial reporting as of December 31, 2024. As a result of the foregoing, KPMG LLP, the Company’s independent registered public accounting firm, has not yet completed its audit procedures, and plans to do so upon the Company’s completion of the aforementioned tasks. The Company currently expects to file its 2024 Form 10-K within the fifteenth calendar day extension provided by Rule 12b-25 (i.e., on or before March 18, 2025). Forward-Looking Statements This Form 12b-25 includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties, including statements regarding the Company’s expected date of filing the 2024 Form 10-K and any changes in the results of operations set forth in the earnings release issued March 3, 2025 as compared to the 2024 Form 10-K
NT 10-K, filed 2025-03-03 · material weakness
ADMA Biologics, Inc. (the “Company”) will be unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) within the prescribed time period without unreasonable effort or expense. As disclosed on its Current Report on Form 8-K filed on October 9, 2024, the Company’s previous independent registered public accounting firm resigned effective as of the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. The Company engaged KPMG LLP as its new independent registered public accounting firm effective as of the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, which was filed on November 7, 2024. The Company requires additional time to test and document the Company’s controls associated with its use of and reliance upon certain third-party service providers and to complete its assessment of the effectiveness of internal control over financial reporting as of December 31, 2024. As a result of the foregoing, KPMG LLP, the Company’s independent registered public accounting firm, has not yet completed its audit procedures, and plans to do so upon the Company’s completion of the aforementioned tasks. The Company currently expects to file its 2024 Form 10-K within the fifteenth calendar day extension provided by Rule 12b-25 (i.e., on or before March 18, 2025). Forward-Looking Statements This Form 12b-25 includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties, including statements regarding the Company’s expected date of filing the 2024 Form 10-K and any changes in the results of operations set forth in the earnings release issued March 3, 2025 as compared to the 2024 Form 10-K
2024-10-31auditor changed or resigned SEC →
2024-10-09auditor changed or resigned SEC →
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice